These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16198056)

  • 1. The future of fulvestrant ("Faslodex").
    Howell A
    Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    Howell A
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of fulvestrant ("Faslodex").
    Howell A; Abram P
    Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant (Faslodex) -- how to make a good drug better.
    Robertson JF
    Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
    Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
    Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    Abram P; Maass N; Rea D; Simon SD; Steger GG
    Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
    Buzdar AU
    Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
    Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L
    Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
    Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
    Chia S; Gradishar W
    Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.
    Dodwell D; Wardley A; Johnston S
    Breast; 2006 Oct; 15(5):584-94. PubMed ID: 16504510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.